Analyst firms · Morgan Stanley · NTRA

Morgan Stanley NTRA price target and rating history

Natera Inc. (NTRA) · Health Care

Morgan Stanley rates Natera Inc. (NTRA) Overweight with a $265 price target, as of its latest action on Dec 2, 2025. It has published 3 rating actions on NTRA since February 2022, including 0 upgrades and 0 downgrades. Across 8 firms with a NTRA price target in the last 12 months, the median target is $305. Morgan Stanley's $265 is 13% below that.

Current rating
Overweight
Price target
$265
Median target, all firms
$305
Actions on NTRA
3

Morgan Stanley price target on NTRA

$265$188$1102023202420252026
Morgan Stanley price target on NTRA, each point a stated target, February 2022 to December 2025.

Every Morgan Stanley rating on NTRA

How other firms rate NTRA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Roth CapitalBuy$475Oct 23, 2026
UBSBuy$435Sep 9, 2026
Rothschild & Co RedburnBuy$385Sep 8, 2026
BernsteinOutperform$310Jun 26, 2026
RBC Capital MarketsOutperform$275Jun 12, 2026
Wolfe ResearchOutperform$260Jun 2, 2026
William BlairOutperformApr 14, 2026
CitigroupBuy$300Jan 7, 2026
Morgan StanleyOverweight$265Dec 2, 2025

Questions about Morgan Stanley and NTRA

What is Morgan Stanley's price target for NTRA?
Morgan Stanley's latest stated price target for Natera Inc. (NTRA) is $265, from its action on Dec 2, 2025.
What is Morgan Stanley's rating on NTRA?
Morgan Stanley rates NTRA Overweight, a bullish rating, as of Dec 2, 2025.
When did Morgan Stanley last change its view on NTRA?
On Dec 2, 2025, Morgan Stanley resumes coverage at Overweight, price target $265.
How does Morgan Stanley's NTRA target compare with other analysts?
Across 8 firms with a NTRA price target in the last 12 months, the median target is $305. Morgan Stanley's $265 is 13% below that.

More NTRA rating histories

All Morgan Stanley ratingsNTRA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.